Zapping resistant tumors with precision radiation may extend the life of current cancer therapy
NCT ID NCT04989725
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This phase II trial tests whether giving focused, high-dose radiation (SABR) to a small number of growing tumors, while continuing the same systemic therapy, can delay overall cancer progression in people with metastatic cancer. About 46 patients whose cancer has started to progress in just 1 to 5 spots will be randomly assigned to either standard care (switching drugs or supportive care) or SABR plus their current treatment. The main question is whether this strategy improves progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- stereotactic ablative radiotherapy (SABR) to oligoprogressive lesions plus continuation of current systemic therapy
- What this could lead to
- If successful, this approach could offer a way to extend the effectiveness of current systemic therapy by zapping resistant spots without switching treatments.
- What could go wrong
- This is a small phase II trial, so results may not apply broadly. Radiation to multiple sites carries risks like fatigue or damage to nearby organs, and the benefit over standard care is unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Hospitalier de l'Université de Montréal
RECRUITINGMontreal, Quebec, H2X 3E4, Canada
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- Genetic roadmaps for advanced cancer: study tests whether expert navigation boosts targeted therapy use
- Double-Drug attack on tough lung cancer mutation
- Zapping spreading tumors could extend life on current cancer drugs
- Zapping stubborn cancer spots may extend life of current drug therapy